文献速递艾滋病与性传播感染

撒哈拉以南非洲PI联合NRTI二线抗逆转录病毒治疗的疗效:系统综述与荟萃分析

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该系统综述与荟萃分析评估了撒哈拉以南非洲使用蛋白酶抑制剂(PI)联合核苷(酸)类逆转录酶抑制剂(NRTI)二线抗逆转录病毒治疗(ART)的病毒学结局。意向性分析显示,治疗48周病毒学抑制率为69.3%(95%CI 58.2%-79.3%),96周为61.5%(95%CI 47.2%-74.9%);病毒学失败者中主要蛋白酶耐药突变中位数为17%(IQR 0-25%)。

要点

  • 二线PI联合NRTI治疗48周病毒学抑制率69.3%,96周降至61.5%。
  • 既往NRTI耐药可提高病毒学抑制的可能性。
  • 病毒学失败者中蛋白酶耐药突变中位17%,随二线治疗时间延长而增加。

核心结论

  • 在撒哈拉以南非洲,约三分之一接受PI联合NRTI二线ART的患者未达到病毒学抑制,但病毒血症患者中蛋白酶耐药不常见。
  • 优化二线ART失败的定义和管理策略是研究重点。

研究设计与样本

  • 系统综述与荟萃分析,纳入报告撒哈拉以南非洲PI为基础二线ART病毒学结局的研究。
  • 主要结局为治疗48周和96周后的病毒学抑制(HIV-1 RNA <400 copies/mL)。
  • 采用DerSimonian-Laird随机效应模型分析汇总数据。

主要发现

  • 意向性分析:48周病毒学抑制率69.3%(95%CI 58.2%-79.3%;4558例,14项研究)。
  • 意向性分析:96周病毒学抑制率61.5%(95%CI 47.2%-74.9%;2145例,8项研究)。
  • 既往NRTI耐药增加病毒学抑制的可能性。
  • 主要蛋白酶耐药突变在病毒学失败人群中位数为17%(IQR 0-25%),随二线ART时间延长而增加。

临床怎么用

  • 应重视二线ART患者的病毒载量监测,识别治疗失败。
  • 对病毒学失败患者需评估蛋白酶耐药,但耐药不常见。
  • 需优化二线ART失败的定义和管理策略。

局限性

  • 病毒载量监测的实施仍面临重大挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In sub-Saharan Africa, 25.5 million people are living with human immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line antiretroviral therapy (ART) is projected to increase in the next decade in keeping with the expansion of treatment provision. Outcome data are required to inform policy. METHODS: We performed a systematic review and meta-analysis of studies reporting the virological outcomes of protease inhibitor (PI)-based second-line ART in sub-Saharan Africa. The primary outcome was virological suppression (HIV-1 RNA <400 copies/mL) after 48 and 96 weeks of treatment. The secondary outcome was the proportion of patients with PI resistance. Pooled aggregate data were analyzed using a DerSimonian-Laird random effects model. RESULTS: By intention-to-treat analysis, virological suppression occurred in 69.3% (95% confidence interval [CI], 58.2%-79.3%) of patients at week 48 (4558 participants, 14 studies), and in 61.5% (95% CI, 47.2%-74.9%) at week 96 (2145 participants, 8 studies). Preexisting resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) increased the likelihood of virological suppression. Major protease resistance mutations occurred in a median of 17% (interquartile range, 0-25%) of the virological failure population and increased with duration of second-line ART. CONCLUSIONS: One-third of patients receiving PI-based second-line ART with continued NRTI use in sub-Saharan Africa did not achieve virological suppression, although among viremic patients, protease resistance was infrequent. Significant challenges remain in implementation of viral load monitoring. Optimizing definitions and strategies for management of second-line ART failure is a research priority. PROSPERO REGISTRATION: CRD42016048985.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stockdale AJ, Saunders MJ, Boyd MA, et al. Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018. PMID: 29272346. doi:10.1093/cid/cix1108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。